Importance of Early Characterization of Physicochemical Properties in Developing High-Dose Intravenous Infusion Regimens for Poorly Water-Soluble Compounds

References

1. 1.↵
   1. Lee Y. C.,
   2. Zocharski P. D.,
   3. Samas B.

   An intravenous formulation decision tree for discovery compound formulation development. Int. J. Pharm. 2003, 253 (1–2), 111–119.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Lipinski C. A.

   Poor aqueous solubility—an industry wide problem in drug discovery. Am. Pharm. Rev. 2002, 5 (3), 82.

   OpenUrl
3. 3.↵
   1. Sweetana S.,
   2. Akers M. J.

   Solubility principles and practices for parenteral drug dosage form development. PDA J. Pharm. Sci. Technol. 1996, 50 (5), 330–342.

   OpenUrlFREE Full Text
4. 4.↵
   1. Nema S.,
   2. Washkuhn R. J.,
   3. Brendel R. J.

   Excipients and their use in injectable products. PDA J. Pharm. Sci. Technol. 1997, 51 (4), 166–171.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Powell M. F.,
   2. Nguyen T.,
   3. Baloian L.

   Compendium of excipients for parenteral formulations. PDA J. Pharm. Sci. Technol. 1998, 52 (5), 238–311.

   OpenUrlFREE Full Text
6. 6.↵
   1. Strickley R. G.

   Parenteral formulations of small molecule therapeutics marketed in the United States (1999). Part III. PDA J. Pharm. Sci. Technol. 2000, 54 (2), 152–169.

   OpenUrlFREE Full Text
7. 7.↵
   1. Strickley R. G.

   Solubilizing excipients in oral and injectable formulations. Pharm. Res. 2004, 21 (2), 201–230.

   OpenUrlCrossRefPubMedWeb of Science
8. 8.↵
   1. Wong J.,
   2. Brugger A.,
   3. Khare A.,
   4. Chaubal M.,
   5. Papadopoulos P.,
   6. Rabinow B.,
   7. Kipp J.,
   8. Ning J.

   Suspensions for intravenous (IV) injection: a review of development, preclinical and clinical aspects. Adv. Drug Del. Rev. 2008, 60 (8), 939–954.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Stahl P. H.,
   2. Wermuth C. G.

   Handbook of Pharmaceutical Salts, Properties, Selection and Use; Verlag Helvetica Chimica Acta: Zürich, 2002; p 334.
10. 10.↵
    1. Yalkowsky S. H.

    Solubilization by Complexation, Solubility and Solubilization in Aqueous Media; Oxford University Press: New York, 1999; p 316.
11. 11.↵
    1. Yalkowsky S. H.,
    2. Krzyzaniak J. F.,
    3. Ward G. H.

    Formulation-related problems associated with intravenous drug delivery. J. Pharm. Sci. 1998, 87 (7), 787–796.

    OpenUrlCrossRefPubMedWeb of Science
12. 12.↵
    1. Bittner B.,
    2. Mountfield R. J.

    Intravenous administration of poorly soluble new drug entities in early drug discovery: the potential impact of formulation on pharmacokinetic parameters. Curr. Opin. Drug Discov. Devel. 2002, 5 (1), 59–71.

    OpenUrlPubMed
13. 13.↵
    1. Kwan Y.

    Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists; Kluwer Academic Publishers: New York, 2002; p 229.
14. 14.↵
    1. Stella V. J.,
    2. He Q.

    Cyclodextrins. Toxicol. Pathol. 2008, 36 (1), 30–42.

    OpenUrlAbstract/FREE Full Text